Search

Your search keyword '"Daalhuisen J"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Daalhuisen J" Remove constraint Author: "Daalhuisen J"
23 results on '"Daalhuisen J"'

Search Results

5. Pharmacological targeting of protease-activated receptor 2 affords protection from bleomycin-induced pulmonary fibrosis

6. Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis

7. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: Potential role in pulmonary fibrosis

8. Does the extend of the culture time of primary hepatocytes in a bioreactor affect the treatment efficacy of a bioartificial liver?

9. Commercially available media for flushing extracorporeal bioartificial liver systems prior to connection to the patient's circulation: an in vitro comparative study in two and three dimensional porcine hepatocyte cultures

13. Commercially Available Media for Flushing Extracorporeal Bioartificial Liver Systems Prior to Connection to the Patient's Circulation: An in vitroComparative Study in Two and Three Dimensional Porcine Hepatocyte Cultures

14. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.

15. Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.

16. Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis.

17. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis.

18. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.

19. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis.

20. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.

21. Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability.

22. Does the extend of the culture time of primary hepatocytes in a bioreactor affect the treatment efficacy of a bioartificial liver?

23. Commercially available media for flushing extracorporeal bioartificial liver systems prior to connection to the patient's circulation: an in vitro comparative study in two and three dimensional porcine hepatocyte cultures.

Catalog

Books, media, physical & digital resources